AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23101951 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 75/25 (BID)
Number of subjects: 2343
Study 23101951 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (QD)
Number of subjects: 2343
Study 23101951 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (QD or BID)
Number of subjects: 2343
Study 23101951 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (QD or BID)
Number of subjects: 2343
Study 23102735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled endotoxin
Number of subjects: 0
Study 23103906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18113
Study 23103906 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (Control)
Number of subjects: 18113
Study 23106023 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 1064
Study 23106923 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 23106988 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-guided three-dimensional repetitive motion training (15-20 daily sessions of 25-30 min each over 4-8 weeks)
Number of subjects: 18
Study 23106988 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-guided three-dimensional repetitive motion training
Number of subjects: 18
Study 23106988 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional, robot-assisted, repetitive motion training
Number of subjects: 18
Study 23107285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mujer Segura intervention
Number of subjects: 80
Study 23107285 — intervention group
Group type: COMPARATOR
Intervention: Standard-care, didactic intervention
Number of subjects: 80
Study 23109089 — intervention group
Group type: EXPERIMENTAL
Intervention: C* risk allele (rs1329650)
Number of subjects: 454
Study 23109692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine at 120 mg/m(2) per day on days 1 through 2 every 3 weeks for six cycles
Number of subjects: 60
Study 23109692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 60
Study 23109697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib with BCR-ABL1 (IS) of > 1% to ≤ 10% at 3 months
Number of subjects: 237
Study 23109697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib with BCR-ABL1 (IS) of > 0.1% to ≤ 1% at 3 months
Number of subjects: 237
Study 23109697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib with BCR-ABL1 (IS) of > 10% at 3 months
Number of subjects: 237
Study 23109697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib with BCR-ABL1 (IS) of ≤ 1% at 3 months
Number of subjects: 237
Study 23109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET after four cycles of R-CHOP (n = 111)
Number of subjects: 121
Study 23109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Final PET at the end of treatment (n = 106)
Number of subjects: 121
Study 23109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET-negative patients
Number of subjects: 121
Study 23109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim PET-positive patients
Number of subjects: 121
Study 23109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Final PET-negative patients
Number of subjects: 121
Study 23109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Final PET-positive patients
Number of subjects: 121
Study 23111057 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg/kg human recombinant granulocyte colony-stimulating factor (hrG-CSF)
Number of subjects: 38
Study 23111363 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly carboplatin, gemcitabine, and bevacizumab
Number of subjects: 35
Study 23111494 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position before induction of general anesthesia
Number of subjects: 63
Study 23111494 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 63
Study 23111494 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 63
Study 23112548 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated pCLE software classification
Number of subjects: 71
Study 23112548 — intervention group
Group type: COMPARATOR
Intervention: Off-line diagnosis by expert endoscopists
Number of subjects: 71
Study 23112822 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.4 mg/kg, range 75-100 mg)
Number of subjects: 27
Study 23113026 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2 grams
Number of subjects: 136
Study 23113026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU
Number of subjects: 136
Study 23113026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EPA and Vitamin E
Number of subjects: 136
Study 23113026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 23113752 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 20
Study 23113777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers citing feeling overwhelmed
Number of subjects: 423
Study 23113777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers citing sleep disturbance
Number of subjects: 423
Study 23113777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers citing financial strain
Number of subjects: 423
Study 23113777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers citing upsetting behavior
Number of subjects: 423
Study 23113777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers citing time demands
Number of subjects: 423
Study 23113909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-reducing treatment decision making
Number of subjects: 12
Study 23113909 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication about treatment options
Number of subjects: 12
Study 23113944 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (average 7.7 kg lost during the weight-loss phase)
Number of subjects: 278
Study 23114055 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 Gy in 18 fractions to the prostate bed (arm 1)
Number of subjects: 80
Study 23114055 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 Gy in 18 fractions to the prostate bed and 45 Gy to the pelvic lymph nodes (arm 2)
Number of subjects: 80
Study 23114278 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 27
Study 23114278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 23114372 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 101
Study 23114372 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-PS
Number of subjects: 101
Study 23114372 — intervention group
Group type: COMPARATOR
Intervention: Vaccine-naive group
Number of subjects: 101
Study 23114473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive colorectal resections
Number of subjects: 105
Study 23114473 — intervention group
Group type: COMPARATOR
Intervention: Screening endoscopy
Number of subjects: 105
Study 23114473 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of desmoid tumors
Number of subjects: 105
Study 23114473 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (BT) and radiotherapy (RT)
Number of subjects: 105
Study 23114473 — intervention group
Group type: COMPARATOR
Intervention: Screening and treatment modalities
Number of subjects: 105
Study 23114473 — intervention group
Group type: COMPARATOR
Intervention: Desmoid tumors
Number of subjects: 105
Study 23115344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by neuropsychological testing)
Number of subjects: 149
Study 23115344 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence (assessed using the Heart Failure Compliance Questionnaire)
Number of subjects: 149
Study 23115630 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-based attention training game system
Number of subjects: 20
Study 23116179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectopic expression of B-function genes (PISTILLATA homologs) in C. parviflora
Number of subjects: 2
Study 23116179 — intervention group
Group type: COMPARATOR
Intervention: Standard sepal-petal species C. arborescens
Number of subjects: 2
Study 23116179 — intervention group
Group type: EXPERIMENTAL
Intervention: C. parviflora
Number of subjects: 2
Study 23116179 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ hybridization analysis of C. parviflora
Number of subjects: 2
Study 23116538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) - Privigen®, dose 0.4 gram/kg, for 6 months
Number of subjects: 9
Study 23116553 — intervention group
Group type: EXPERIMENTAL
Intervention: AKR1C3 IVS4-212 GG genotype
Number of subjects: 151
Study 23116553 — intervention group
Group type: EXPERIMENTAL
Intervention: CBR3 G11A
Number of subjects: 151
Study 23116553 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 G2677T/A
Number of subjects: 151
Study 23116553 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 IVS26+59 T>G
Number of subjects: 151
Study 23116553 — intervention group
Group type: EXPERIMENTAL
Intervention: AKR1C3 IVS4-212 C<G genotype
Number of subjects: 151
Study 23116602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st, 2nd, 3rd line treatments for CML
Number of subjects: 900
Study 23116602 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated phase (AP) and blast phase (BP) treatments
Number of subjects: 900
Study 23116602 — intervention group
Group type: EXPERIMENTAL
Intervention: CML treatments
Number of subjects: 900
Study 23117560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycling to school
Number of subjects: 43
Study 23117560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in lifestyle)
Number of subjects: 43
Study 23117571 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based epidemiology of viral respiratory infections (ARI)
Number of subjects: 0
Study 23117571 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based epidemiology of gastrointestinal infections (AGE)
Number of subjects: 0
Study 23117571 — intervention group
Group type: COMPARATOR
Intervention: Control material from children without symptoms
Number of subjects: 0
Study 23117571 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses of specific respiratory and gastrointestinal pathogens
Number of subjects: 0
Study 23117698 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects aged ≥45 years
Number of subjects: 803
Study 23117698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging HIV-infected patients (≥45 years)
Number of subjects: 803
Study 23117698 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, smoking, advanced symptomatic HIV infection
Number of subjects: 803
Study 23117698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging HIV-infected subjects (≥45 years)
Number of subjects: 803
Study 23118111 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted erosion segmentation volume measurement
Number of subjects: 32
Study 23118111 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)
Number of subjects: 32
Study 23118111 — intervention group
Group type: COMPARATOR
Intervention: MRI measures (both methods)
Number of subjects: 32
Study 23118111 — intervention group
Group type: COMPARATOR
Intervention: Construct correlational validity of MRI methods
Number of subjects: 32
Study 23118111 — intervention group
Group type: COMPARATOR
Intervention: DAS28
Number of subjects: 32
Study 23118116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg infusion at months 0 and 6 with 100 mg methylprednisolone
Number of subjects: 8
Study 23118984 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine (1.5×10^8 pfu)
Number of subjects: 30
Study 23118984 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine
Number of subjects: 30
Study 23119077 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of clinical preventive services recommendations
Number of subjects: 0
Study 23119077 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of prioritization according to MoH guidelines
Number of subjects: 0
Study 23119077 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation rates by level of training
Number of subjects: 0
Study 23119077 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall knowledge of preventive services
Number of subjects: 0
Study 23119077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritization of preventive services
Number of subjects: 0
Study 23121323 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900
Study 23121323 — intervention group
Group type: COMPARATOR
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 1900
Study 23122784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg, orally daily) plus capecitabine (2000 mg/m², orally from day 1 to day 14)
Number of subjects: 45
Study 23122784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 45
Study 23124321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg) administered on days 1 and 15
Number of subjects: 19
Study 23128051 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation for OCD
Number of subjects: 0
Study 23128154 — intervention group
Group type: EXPERIMENTAL
Intervention: v1.0 smoking cessation quit success genotype score
Number of subjects: 0
Study 23129135 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV) in patients with type 2 diabetes
Number of subjects: 89
Study 23129135 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (PWV)
Number of subjects: 89
Study 23129163 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acuity Rating (PAR) score provided by the primary team
Number of subjects: 48
Study 23129163 — intervention group
Group type: COMPARATOR
Intervention: Primary team's PAR score
Number of subjects: 48
Study 23129758 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of acute HIV infection at enrollment
Number of subjects: 2067
Study 23129758 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of HIV seroconversion
Number of subjects: 2067
Study 23129758 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of recent HIV infection using multiassay algorithm (MAA)
Number of subjects: 2067
Study 23130114 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in RCTs of type 2 diabetes mellitus (specific interventions not detailed in the abstract)
Number of subjects: 91842
Study 23130114 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection for renal disease (defined by decline in renal function or presence of proteinuria)
Number of subjects: 91842
Study 23130114 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cardiovascular morbidity
Number of subjects: 91842
Study 23130114 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion and exclusion criteria of RCTs
Number of subjects: 91842
Study 23130118 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 229
Study 23130118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 229
Study 23130118 — intervention group
Group type: COMPARATOR
Intervention: Control (Clopidogrel)
Number of subjects: 229
Study 23130122 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 300
Study 23130122 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 300
Study 23130134 — intervention group
Group type: EXPERIMENTAL
Intervention: n3-PUFAs 2 g orally twice daily (minimum of 6 g)
Number of subjects: 260
Study 23130134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 23130134 — intervention group
Group type: EXPERIMENTAL
Intervention: n3-PUFAs
Number of subjects: 260
Study 23130134 — intervention group
Group type: COMPARATOR
Intervention: n3-PUFAs and Placebo
Number of subjects: 260
Study 23130135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d
Number of subjects: 1001
Study 23130135 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d
Number of subjects: 1001
Study 23130135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d with high on-aspirin RPR and low von Willebrand factor
Number of subjects: 1001
Study 23130135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d with high on-aspirin RPR and low platelet count
Number of subjects: 1001
Study 23130154 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain prevention program for stroke and dementia
Number of subjects: 3908
Study 23130154 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 3908
Study 23130162 — intervention group
Group type: EXPERIMENTAL
Intervention: End-diastolic IMT
Number of subjects: 5633
Study 23130162 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-systolic IMT
Number of subjects: 5633
Study 23130162 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in carotid IMT during the cardiac cycle
Number of subjects: 5633
Study 23130162 — intervention group
Group type: COMPARATOR
Intervention: Peak-systolic IMT reference values
Number of subjects: 5633
Study 23130172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg daily
Number of subjects: 36
Study 23130172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23131206 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg PhtD vaccine candidate
Number of subjects: 63
Study 23131206 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg PhtD vaccine candidate
Number of subjects: 63
Study 23131206 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg PhtD vaccine candidate
Number of subjects: 63
Study 23131206 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose levels of PhtD vaccine candidate
Number of subjects: 63
Study 23131904 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA genetic testing
Number of subjects: 775
Study 23134762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral cholecalciferol (vitamin D3)
Number of subjects: 480
Study 23134762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 23134813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal suctioning maneuver using a 16-French suction catheter with a suction pressure of -400 mbar.
Number of subjects: 25
Study 23134813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal suctioning maneuver
Number of subjects: 25
Study 23135257 — intervention group
Group type: EXPERIMENTAL
Intervention: FA global model
Number of subjects: 57
Study 23135257 — intervention group
Group type: EXPERIMENTAL
Intervention: FA selected model
Number of subjects: 57
Study 23135257 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient model
Number of subjects: 57
Study 23135257 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical classifiers model
Number of subjects: 57
Study 23136057 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation (BSD)
Number of subjects: 203
Study 23136848 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQB1*0602 allele-positive individuals with OSAS
Number of subjects: 894
Study 23136848 — intervention group
Group type: COMPARATOR
Intervention: HLA-DQB1*0602 allele-negative individuals with OSAS
Number of subjects: 894
Study 23136848 — intervention group
Group type: COMPARATOR
Intervention: Individuals without OSAS
Number of subjects: 894
Study 23136929 — intervention group
Group type: EXPERIMENTAL
Intervention: DAFNE delivered over five consecutive days (1 week course)
Number of subjects: 213
Study 23136929 — intervention group
Group type: COMPARATOR
Intervention: DAFNE delivered one day a week over five weeks (5 week course)
Number of subjects: 213
Study 23137499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of 1 × 10(5)/kg or 5 × 10(5)/kg CD34(+) cells
Number of subjects: 167
Study 23137499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 23137499 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF-mediated stem cell mobilization
Number of subjects: 167
Study 23137723 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattention symptoms
Number of subjects: 401
Study 23138190 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 40
Study 23138404 — intervention group
Group type: EXPERIMENTAL
Intervention: Draft expectations survey (Phase 1)
Number of subjects: 25
Study 23138404 — intervention group
Group type: EXPERIMENTAL
Intervention: Draft expectations survey (Phase 2)
Number of subjects: 25
Study 23138404 — intervention group
Group type: EXPERIMENTAL
Intervention: Final expectations survey (Phase 3)
Number of subjects: 25
Study 23138680 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 681
Study 23138731 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-resistant virus
Number of subjects: 0
Study 23139273 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens sensor (CLS) monitoring during 24-hour IOP monitoring, two sessions 1 week apart.
Number of subjects: 40
Study 23140536 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (target plasma levels between 4 and 8 ng/ml)
Number of subjects: 17
Study 23140536 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 17
Study 23140654 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 101
Study 23141679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanochemical endovenous ablation (MOCA)
Number of subjects: 68
Study 23141679 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 68
Study 23141679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MOCA and RFA
Number of subjects: 68
Study 23142061 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 monotherapy (200 mg once daily for 7 days)
Number of subjects: 37
Study 23142076 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery
Number of subjects: 55
Study 23142076 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval surgery after NACT
Number of subjects: 55